Vascular KCa-channels as therapeutic targets in hypertension and restenosis disease

Ralf Köhler, Brajesh P. Kaistha, Heike Wulff

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

Importance of the field: Cardiovascular disease is a leading cause of death in modern societies. Hyperpolarizing Ca2+-activated K+ channels (KCa) are important membrane proteins in the control of arterial tone and pathological vascular remodelling and thus could serve as new drug targets. Areas covered in this review: We summarize recent advances in the field of vascular KCa and their roles in cardiovascular pathologies such as hypertension and restenosis disease and draw attention to novel small-molecule channel modulators and their possible therapeutic utility. This review focuses on literature from the last four to five years. What the reader will gain: Pharmacological opening of endothelial KCa3.1/ KCa2.3 channels stimulates endothelium-derived-hyperpolarizing-factormediated arteriolar dilation and lowers blood pressure. Inhibition of smooth muscle KCa3.1 channels has beneficial effects in restenosis disease and atherosclerosis. We consider the therapeutic potential of KCa3.1/KCa2.3 openers as novel endothelium-specific antihypertensive drugs as well as of KCa3.1- blockers for the treatment of pathological vascular remodelling and discuss advantages and disadvantages of the pharmacotherapeutic approaches. Take home message: Pharmacological manipulation of vascular KCa channels by novel small-molecule modulators offers new venues for alternative treatments of hypertension, restenosis and atherosclerosis. Additional efforts are required to optimize these compounds and to validate them as cardiovascular-protective drugs.

Original languageEnglish (US)
Pages (from-to)143-155
Number of pages13
JournalExpert Opinion on Therapeutic Targets
Volume14
Issue number2
DOIs
StatePublished - Feb 2010

Fingerprint

Endothelium
Blood Vessels
Atherosclerosis
Pharmacology
Hypertension
Calcium-Activated Potassium Channels
Protective Agents
Cardiovascular Agents
Modulators
Antihypertensive Agents
Smooth Muscle
Dilatation
Cause of Death
Membrane Proteins
Molecules
Cardiovascular Diseases
Blood pressure
Pathology
Blood Pressure
Muscle

Keywords

  • Antihypertensives
  • Ca-activated K channels
  • EDHF
  • Hypertension
  • KCa2.3
  • KCa3.1
  • Restenosis

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

Vascular KCa-channels as therapeutic targets in hypertension and restenosis disease. / Köhler, Ralf; Kaistha, Brajesh P.; Wulff, Heike.

In: Expert Opinion on Therapeutic Targets, Vol. 14, No. 2, 02.2010, p. 143-155.

Research output: Contribution to journalArticle

@article{cd9b86ec4d574a85847dbd3051d84afd,
title = "Vascular KCa-channels as therapeutic targets in hypertension and restenosis disease",
abstract = "Importance of the field: Cardiovascular disease is a leading cause of death in modern societies. Hyperpolarizing Ca2+-activated K+ channels (KCa) are important membrane proteins in the control of arterial tone and pathological vascular remodelling and thus could serve as new drug targets. Areas covered in this review: We summarize recent advances in the field of vascular KCa and their roles in cardiovascular pathologies such as hypertension and restenosis disease and draw attention to novel small-molecule channel modulators and their possible therapeutic utility. This review focuses on literature from the last four to five years. What the reader will gain: Pharmacological opening of endothelial KCa3.1/ KCa2.3 channels stimulates endothelium-derived-hyperpolarizing-factormediated arteriolar dilation and lowers blood pressure. Inhibition of smooth muscle KCa3.1 channels has beneficial effects in restenosis disease and atherosclerosis. We consider the therapeutic potential of KCa3.1/KCa2.3 openers as novel endothelium-specific antihypertensive drugs as well as of KCa3.1- blockers for the treatment of pathological vascular remodelling and discuss advantages and disadvantages of the pharmacotherapeutic approaches. Take home message: Pharmacological manipulation of vascular KCa channels by novel small-molecule modulators offers new venues for alternative treatments of hypertension, restenosis and atherosclerosis. Additional efforts are required to optimize these compounds and to validate them as cardiovascular-protective drugs.",
keywords = "Antihypertensives, Ca-activated K channels, EDHF, Hypertension, KCa2.3, KCa3.1, Restenosis",
author = "Ralf K{\"o}hler and Kaistha, {Brajesh P.} and Heike Wulff",
year = "2010",
month = "2",
doi = "10.1517/14728220903540257",
language = "English (US)",
volume = "14",
pages = "143--155",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Vascular KCa-channels as therapeutic targets in hypertension and restenosis disease

AU - Köhler, Ralf

AU - Kaistha, Brajesh P.

AU - Wulff, Heike

PY - 2010/2

Y1 - 2010/2

N2 - Importance of the field: Cardiovascular disease is a leading cause of death in modern societies. Hyperpolarizing Ca2+-activated K+ channels (KCa) are important membrane proteins in the control of arterial tone and pathological vascular remodelling and thus could serve as new drug targets. Areas covered in this review: We summarize recent advances in the field of vascular KCa and their roles in cardiovascular pathologies such as hypertension and restenosis disease and draw attention to novel small-molecule channel modulators and their possible therapeutic utility. This review focuses on literature from the last four to five years. What the reader will gain: Pharmacological opening of endothelial KCa3.1/ KCa2.3 channels stimulates endothelium-derived-hyperpolarizing-factormediated arteriolar dilation and lowers blood pressure. Inhibition of smooth muscle KCa3.1 channels has beneficial effects in restenosis disease and atherosclerosis. We consider the therapeutic potential of KCa3.1/KCa2.3 openers as novel endothelium-specific antihypertensive drugs as well as of KCa3.1- blockers for the treatment of pathological vascular remodelling and discuss advantages and disadvantages of the pharmacotherapeutic approaches. Take home message: Pharmacological manipulation of vascular KCa channels by novel small-molecule modulators offers new venues for alternative treatments of hypertension, restenosis and atherosclerosis. Additional efforts are required to optimize these compounds and to validate them as cardiovascular-protective drugs.

AB - Importance of the field: Cardiovascular disease is a leading cause of death in modern societies. Hyperpolarizing Ca2+-activated K+ channels (KCa) are important membrane proteins in the control of arterial tone and pathological vascular remodelling and thus could serve as new drug targets. Areas covered in this review: We summarize recent advances in the field of vascular KCa and their roles in cardiovascular pathologies such as hypertension and restenosis disease and draw attention to novel small-molecule channel modulators and their possible therapeutic utility. This review focuses on literature from the last four to five years. What the reader will gain: Pharmacological opening of endothelial KCa3.1/ KCa2.3 channels stimulates endothelium-derived-hyperpolarizing-factormediated arteriolar dilation and lowers blood pressure. Inhibition of smooth muscle KCa3.1 channels has beneficial effects in restenosis disease and atherosclerosis. We consider the therapeutic potential of KCa3.1/KCa2.3 openers as novel endothelium-specific antihypertensive drugs as well as of KCa3.1- blockers for the treatment of pathological vascular remodelling and discuss advantages and disadvantages of the pharmacotherapeutic approaches. Take home message: Pharmacological manipulation of vascular KCa channels by novel small-molecule modulators offers new venues for alternative treatments of hypertension, restenosis and atherosclerosis. Additional efforts are required to optimize these compounds and to validate them as cardiovascular-protective drugs.

KW - Antihypertensives

KW - Ca-activated K channels

KW - EDHF

KW - Hypertension

KW - KCa2.3

KW - KCa3.1

KW - Restenosis

UR - http://www.scopus.com/inward/record.url?scp=74949130493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74949130493&partnerID=8YFLogxK

U2 - 10.1517/14728220903540257

DO - 10.1517/14728220903540257

M3 - Article

C2 - 20055714

AN - SCOPUS:74949130493

VL - 14

SP - 143

EP - 155

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

IS - 2

ER -